Coinfection
CROI 2017: DAA Therapy Cures HIV/HCV Coinfected People with Decompensated Cirrhosis or Transplants
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 08 March 2017 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for hepatitis C, according to 3 Spanish studies presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle.
CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 18 February 2017 00:00
- Written by Liz Highleyman
AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 21 November 2016 00:00
- Written by Liz Highleyman
More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C -- including many with liver cirrhosis -- achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce results as good as those seen in formal clinical trials, according to results from a Spanish study presented at the AASLD Liver Meeting this month in Boston.
CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands
- Details
- Category: HCV Sexual Transmission
- Published on Friday, 17 February 2017 00:00
- Written by Liz Highleyman
A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle.
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Sunday, 20 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/20/16
CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- Details
- Category: HCV Disease Progression
- Published on Friday, 17 February 2017 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
Coverage of IDWeek 2016
- Details
- Category: HIV Treatment
- Published on Friday, 04 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.
Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.
Full listing of coverage by topic
11/4/16
AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 22 November 2016 00:00
- Written by Liz Highleyman
The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver Meeting this month in Boston.
Improved HIV Treatment Has Not Reduced End-Stage Liver Disease in HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 19 October 2016 00:00
- Written by Michael Carter
Incidence of end-stage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the U.S. report in the November 1 edition of Clinical Infectious Diseases.